Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Intact PTH and Bio-Intact PTH Assays Among Non-Dialysis Dependent Chronic Kidney Disease Patients

  • Einbinder, Yael (Department of Nephrology and Hypertension, Meir Medical Center) ;
  • Benchetrit, Sydney (Department of Nephrology and Hypertension, Meir Medical Center) ;
  • Golan, Eliezer (Department of Nephrology and Hypertension, Meir Medical Center) ;
  • Zitman-Gal, Tali (Department of Nephrology and Hypertension, Meir Medical Center)
  • Received : 2016.12.18
  • Accepted : 2017.06.02
  • Published : 2017.09.01
⟨ Previous Next ⟩

Abstract

Background: The third-generation bio-intact parathyroid hormone (PTH) (1-84) assay was designed to overcome problems associated with the detection of C-terminal fragments by the second-generation intact PTH assay. The two assays have been compared primarily among dialysis populations. The present study evaluated the correlations and differences between these two PTH assays among patients with chronic kidney disease (CKD) stages 3 to 5 not yet on dialysis. Methods: Blood samples were collected from 98 patients with CKD stages 3 to 5. PTH concentrations were measured simultaneously by using the second-generation - PTH intact-STAT and third-generation bio-intact 1-84 PTH assays. Other serum biomarkers of bone mineral disorders were also assessed. CKD stage was calculated by using the CKD-Epidemiology Collaboration (EPI) formula. Results: Serum bio-intact PTH concentrations were strongly correlated but significantly lower than the intact PTH concentrations (r=0.963, P <0.0001). This finding was consistent among CKD stages 3 to 5. PTH concentrations by both assays (intact and bio-intact PTH) positively correlated with urea (r=0.523, r=0.504; P =0.002, respectively), phosphorus (r=0.532, r=0.521; P <0.0001, respectively) and negatively correlated with blood calcium (r=-0.435, r=-0.476; P <0.0001, respectively), 25(OH) vitamin D, (r=-0.319, r=-0.353; respectively, P <0.0001) and the estimated glomerular filtration rate (r=-0.717, r=-0.688; P <0.0001, respectively). Conclusions: Among patients with CKD stages 3 to 5 not on dialysis, the bio-intact PTH assay detected significantly lower PTH concentrations compared with intact PTH assay. Additional studies that correlate the diagnosis and management of CKD mineral and bone disorders with bone histomorphometric findings are needed to determine whether bio-intact PTH assay results are better surrogate markers in these early stages of CKD.

Keywords

References

  1. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 2014;85:142-50. https://doi.org/10.1038/ki.2013.271
  2. Isakova T, Wahl P, Vargas GS, Guticrrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-8. https://doi.org/10.1038/ki.2011.47
  3. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8. https://doi.org/10.1038/sj.ki.5002009
  4. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5:286-91. https://doi.org/10.2215/CJN.05420709
  5. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2015; 87:502-28. https://doi.org/10.1038/ki.2014.425
  6. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barrc M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-9.
  7. D'Amour P and Brossard JH. Carboxyl-terminal parathyroid hormone fragments: role in parathyroid hormone physiopathology. Curr Opin Nephrol Hypertens 2005;14:330-6. https://doi.org/10.1097/01.mnh.0000172718.49476.64
  8. Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010;77:93-100. https://doi.org/10.1038/ki.2009.374
  9. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-44. https://doi.org/10.1016/0272-6386(95)90453-0
  10. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-50.
  11. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14. https://doi.org/10.1359/jbmr.2001.16.4.605
  12. Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone 2009;44:666-70. https://doi.org/10.1016/j.bone.2008.12.016
  13. van Ballegooijen AJ, Rhee EP, Elmariah S, de Boer IH, Kestenbaum B. Renal clearance of mineral metabolism biomarkers. J Am Soc Nephrol 2016;27:392-7. https://doi.org/10.1681/ASN.2014121253
  14. Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, Krisper P, Holzer H, Malluche HH, et al. Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease. Clin Nephrol 2006;65:328-34. https://doi.org/10.5414/CNP65328
  15. O'Flaherty D, Sankaralingam A, Scully P, Manghat P, Goldsmith D, Hampson G. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD). Clin Biochem 2013;46:1405-9. https://doi.org/10.1016/j.clinbiochem.2013.06.023
  16. Tan K, Ong L, Sethi SK, Saw S. Comparison of the Elecsys PTH(1-84) assay with four contemporary second generation intact PTH assays and association with other biomarkers in chronic kidney disease patients. Clin Biochem 2013;46:781-6. https://doi.org/10.1016/j.clinbiochem.2013.01.016
  17. Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005;68:1206-14. https://doi.org/10.1111/j.1523-1755.2005.00513.x
  18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
  19. Sturgeon CM, Sprague SM, Metcalfe W. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant 2011;26:3440-5. https://doi.org/10.1093/ndt/gfr614
  20. Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, et al. Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem 2004;50:385-90. https://doi.org/10.1373/clinchem.2003.026831
  21. Gannagc-Yared MH, Fares C, Ibrahim T, Rahal ZA, Elias M, Chelala D. Comparison between a second and a third generation parathyroid hormone assay in hemodialysis patients. Metabolism 2013;62:1416-22. https://doi.org/10.1016/j.metabol.2013.05.007
  22. Melamed ML, Eustace JA, Plantinga LC, Jaar BG, Fink NE, Parekh RS, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008;23:1650-8. https://doi.org/10.1093/ndt/gfm849
  23. Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012;27:1950-6. https://doi.org/10.1093/ndt/gfr535
  24. Fujimori A, Sakai M, Yoshiya K, Shin J, Kim JI, Inaba Y, et al. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Ther Apher Dial 2004;8:474-9. https://doi.org/10.1111/j.1774-9987.2004.00189.x
  25. Hecking M, Kainz A, Bielesz B, Plischke M, Beilhack G, Horl WH, et al. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients. Clin Biochem 2012;45:1645-51. https://doi.org/10.1016/j.clinbiochem.2012.08.006
  26. Silver J and Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int Suppl 2005:S8-12.
  27. Silver J and Naveh-Many T. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013;9:641-9.
  28. Kajbaf F, Mentaverri R, Diouf M, Fournier A, Kamel S, Lalau JD. The association between 25-Hydroxyvitamin D and Hemoglobin A1c levels in patients with type 2 diabetes and stage 1-5 chronic kidney disease. Int J Endocrinol 2014; 2014:142468.
  29. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99: 3570-9. https://doi.org/10.1210/jc.2014-1414
  30. Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5. Clin Nephrol 2008;70:296-305. https://doi.org/10.5414/CNP70296
  31. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 2016; 67:559-66. https://doi.org/10.1053/j.ajkd.2015.06.023
  32. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011;26:1368-76. https://doi.org/10.1002/jbmr.309

Cited by

  1. Moving from the second to the third generation Roche PTH assays: what are the consequences for clinical practice? vol.57, pp.2, 2019, https://doi.org/10.1515/cclm-2018-0300
  2. Clinical Guidelines and PTH Measurement: Does Assay Generation Matter? vol.40, pp.6, 2017, https://doi.org/10.1210/er.2018-00220
  3. Comparison of Second- and Third-Generation Parathyroid Hormone Test Results in Patients with Chronic Kidney Disease vol.26, pp.None, 2020, https://doi.org/10.12659/msm.928301